Open-label trial compared cannabis, oxycodone, and their combination for fibromyalgia pain
In a proof-of-concept trial, pharmaceutical-grade cannabis and its combination with oxycodone were tested against oxycodone alone for fibromyalgia, exploring whether cannabis could enable lower opioid doses.
Quick Facts
What This Study Found
The SPIRAL study randomized fibromyalgia patients to three arms: cannabis alone, oxycodone alone, or cannabis+oxycodone combination. The trial examined whether combining cannabis with opioids could maintain pain relief while reducing opioid consumption.
Key Numbers
Three treatment arms: cannabis alone, oxycodone alone, cannabis+oxycodone combination. Pharmaceutical-grade cannabis used. Proof-of-concept design.
How They Did This
Single-center, randomized, three-arm, open-label, proof-of-concept study. Fibromyalgia patients randomized to pharmaceutical-grade cannabis, oxycodone, or cannabis/oxycodone combination.
Why This Research Matters
If cannabis can allow lower opioid doses while maintaining pain control, it could reduce opioid-related harms in chronic pain populations. This is the first trial directly testing this combination approach in fibromyalgia.
The Bigger Picture
The opioid-sparing potential of cannabis is frequently discussed but rarely tested in controlled trials. This study directly addresses whether combining the two produces better outcomes than either alone in a chronic pain population.
What This Study Doesn't Tell Us
Open-label design introduces significant expectation bias. Single-center. Proof-of-concept with likely small sample. Fibromyalgia results may not generalize to other chronic pain conditions. Pharmaceutical-grade cannabis may not reflect commercial products.
Questions This Raises
- ?Would a double-blind trial confirm these preliminary findings?
- ?What is the optimal cannabis-opioid dose ratio for pain relief with minimal side effects?
Trust & Context
- Key Stat:
- First trial directly comparing cannabis, opioid, and combination therapy for fibromyalgia
- Evidence Grade:
- Randomized but open-label proof-of-concept trial. Important first step but expectation bias and small scale limit conclusions.
- Study Age:
- Published 2023.
- Original Title:
- Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study.
- Published In:
- Trials, 24(1), 64 (2023)
- Authors:
- van Dam, Cornelis Jan(2), van Velzen, Monique(3), Kramers, Cornelis(2), Schellekens, Arnt, Olofsen, Erik, Niesters, Marieke, Dahan, Albert
- Database ID:
- RTHC-04994
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Can cannabis replace opioids for pain?
This trial tested that question directly by comparing cannabis alone, oxycodone alone, and their combination for fibromyalgia. While the proof-of-concept design provides preliminary data, the open-label format means patients knew what they were receiving, which can significantly influence pain perception and reporting.
Is it safe to combine cannabis and opioids?
Some research suggests cannabis and opioids may have complementary pain-relieving mechanisms. However, both substances affect cognitive function and sedation. Any combination approach requires careful medical supervision and monitoring for additive side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04994APA
van Dam, Cornelis Jan; van Velzen, Monique; Kramers, Cornelis; Schellekens, Arnt; Olofsen, Erik; Niesters, Marieke; Dahan, Albert. (2023). Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study.. Trials, 24(1), 64. https://doi.org/10.1186/s13063-023-07078-6
MLA
van Dam, Cornelis Jan, et al. "Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study.." Trials, 2023. https://doi.org/10.1186/s13063-023-07078-6
RethinkTHC
RethinkTHC Research Database. "Cannabis-opioid interaction in the treatment of fibromyalgia..." RTHC-04994. Retrieved from https://rethinkthc.com/research/van-2023-cannabisopioid-interaction-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.